Page last updated: 2024-11-12

bms-650032

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

asunaprevir: an NS3 protease inhibitor against hepatitis C virus [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID16076883
CHEMBL ID2105735
CHEBI ID134723
SCHEMBL ID2630655
MeSH IDM0573380

Synonyms (54)

Synonym
HY-14434
carbamic acid, [(1s)-1-[[(2s,4r)-4-[(7-chloro-4-methoxy-1-isoquinolinyl)oxy]-2-[[[(1r,2s)-1-[[(cyclopropylsulfonyl)amino]carbonyl]-2-ethenylcyclopropyl]amino]carbonyl]-1-pyrrolidinyl]carbonyl]-2,2-dimethylpropyl]-, 1,1-dimethylethyl ester
tert-butyl n-[(1s)-1-[(2s,4r)-4-[(7-chloro-4-methoxy-1-isoquinolyl)oxy]-2-[[(1r,2s)-1-(cyclopropylsulfonylcarbamoyl)-2-vinyl-cyclopropyl]carbamoyl]pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]carbamate
CHEBI:134723
asunaprevir
bms-650032
bms 650032
bdbm50287594
asunaprevir (jan/usan)
sunvepra (tn)
D10093
630420-16-5
bms650032
unii-s9x0krj00s
1,1-dimethylethyl ((1s)-1-(((2s,4r)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2- (((1r,2s)-1-((cyclopropylsulfonyl)carbamoyl)-2-ethenylcyclopropyl)carbamoyl) pyrrolidin-1-yl)carbonyl)-2,2-dimethylpropyl)carbamate
1,1-dimethylethyl ((1s)-1-{((2s,4r)-4-(7-chloro-4-methoxyisoquinolin-1-yloxy)-2-({(1r,2s)-1-((cyclopropylsulfonyl)carbamoyl)-2-ethenylcyclopropyl}carbamoyl) pyrrolidin-1-yl)carbonyl}-2,2-dimethylpropyl)carbamate
cyclopropanecarboxamide, n-((1,1-dimethylethoxy)carbonyl)-3-methyl-l-valyl-(4r)-4- ((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-l-prolyl-1-amino-n-(cyclopropylsulfonyl)-2- ethenyl-, (1r,2s)-
asunaprevir [usan:inn]
s9x0krj00s ,
cyclopropanecarboxamide, n-((1,1-dimethylethoxy)carbonyl)-3-methyl-l-valyl-(4r)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-l-prolyl-1-amino-n-(cyclopropylsulfonyl)-2-ethenyl-, (1r,2s)-
CHEMBL2105735
sunvepra
n-(tert-butoxycarbonyl)-3-methyl-l-valyl-(4r)-4-[(7-chloro-4-methoxyisoquinolin-1-yl)oxy]-n-{(1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}-l-prolinamide
2r9 ,
CS-0674
asunaprevir [who-dd]
asunaprevir [jan]
asunaprevir [inn]
tert-butyl ((2s)-1-((2s,4r)-4-((7-chloro-4-methoxyisoquinolin-1-yl)oxy)-2-(((1r,2s)-1-((cyclopropanesulfonyl)carbamoyl)-2-ethenylcyclopropyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)carbamate
asunaprevir [mi]
asunaprevir [usan]
SCHEMBL2630655
tert-butyl ((s)-1-((2s,4r)-4-((7-chloro-4-methoxyisoquinolin-1-yl)oxy)-2-(((1r,2s)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)carbamate
EX-A386
(1r,2s)-n-[(1,1-dimethylethoxy)carbonyl]-3-methyl-l-valyl-(4r)-4-[(7-chloro-4-methoxy-1-isoquinolinyl)oxy]-l-prolyl-1-amino-n-(cyclopropylsulfonyl)-2-ethenylcyclopropanecarboxamide
asunaprevir; bms-650032
mfcd27987900
DB11586
BCP08230
asunaprevir;bms650032;bms-650032
Q4811881
tert-butyl n-[(2s)-1-[(2s,4r)-4-(7-chloro-4-methoxyisoquinolin-1-yl)oxy-2-[[(1r,2s)-1-(cyclopropylsulfonylcarbamoyl)-2-ethenylcyclopropyl]carbamoyl]pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate
AMY38775
sunvepratrade
gtpl10882
compound 24 [pmid: 24564672]
NCGC00378691-02
A857563
bms650032;(1r,2s)-n-[(1,1-dimethylethoxy)carbonyl]-3-methyl-l-valyl-(4r)-4-[(7-chloro-4-methoxy-1-isoquinolinyl)oxy]-l-prolyl-1-amino-n-(cyclopropylsulfonyl)-2-ethenylcyclopropanecarboxamide
NCGC00378691-05
AKOS037515831
DTXSID201026065
EN300-20059992
tert-butyl n-[(2s)-1-[(2s,4r)-4-[(7-chloro-4-methoxyisoquinolin-1-yl)oxy]-2-{[(1r,2s)-1-[(cyclopropanesulfonyl)carbamoyl]-2-ethenylcyclopropyl]carbamoyl}pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" DCV and ASV were generally well tolerated, with no serious adverse events or clinicallyrelevant changes in vital signs or ECG parameters."( Single- and multiple-ascending dose studies to evaluate the safety, tolerability, and pharmacokinetics of daclatasvir and asunaprevir in healthy male Japanese subjects.
Bertz, RJ; Bifano, M; Eley, T; Hiraoka, M; Nagashima, H; Shiozaki, T; Ueno, T; Yamahira, N, 2015
)
0.42
" Daclastavir is generally safe and well tolerated, with a low barrier to resistance and low potential for drug-drug interaction."( Review article: the efficacy and safety of daclatasvir in the treatment of chronic hepatitis C virus infection.
Bunchorntavakul, C; Reddy, KR, 2015
)
0.42
" DCV + ASV had lower adverse events rates than comparators."( Comparative efficacy and safety of daclatasvir/asunaprevir versus IFN-based regimens in genotype 1b hepatitis C virus infection.
Behl, AS; Betts, KA; Kalsekar, A; Li, J; Signorovitch, JE; Song, Y; Sorg, RA, 2015
)
0.42
" We evaluated the 12-week sustained virologic response (SVR12) and adverse events during treatment."( Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C.
Furuya, K; Horimoto, H; Izumi, T; Kimura, M; Kobayashi, T; Konno, J; Kudo, M; Morikawa, K; Nagasaka, A; Nakai, M; Natsuizaka, M; Ogawa, K; Sakamoto, N; Sato, F; Shinada, K; Sho, T; Suda, G; Tateyama, M; Terashita, K; Tsukuda, Y; Tsunematsu, S; Umemura, M; Yamamoto, Y; Yamasaki, K, 2016
)
0.43
"To review adverse events (AEs) uniquely associated with DAA therapy across a broad spectrum of patient populations."( Review article: safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy.
Banerjee, D; Reddy, KR, 2016
)
0.43
" No adverse constitutional events were observed in either of the groups."( Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis.
Iio, E; Ishikawa, T; Kumada, T; Tada, T; Takaguchi, K; Tanaka, Y; Toyoda, H; Tsuji, K; Zeniya, M, 2016
)
0.43
" Recently, interferon-ribavirin free direct acting antivirals (DAAs) treatment has shown strong efficacy and fewer adverse events for chronic HCV infection patients without using dialysis, but there are few reports about DAAs for such patients."( Effect and Safety of Daclatasvir-Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b -Infected Patients on Hemodialysis.
Miyagi, K; Miyazaki, R, 2016
)
0.43
" DCV and ASV were well tolerated in most of the patients, with treatment discontinuation due to adverse events (elevated liver enzyme and decompensation) occurring in two patients."( Efficacy and safety of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infection.
Lee, HL; Nam, HC; Song, MJ; Yang, H, 2016
)
0.43
"In this study, combination of DCV and ASV treatment achieved a high sustained virological response with few adverse events even in those with cirrhosis, advanced age, and nonresponse/relapse to previous interferon-based therapy."( Efficacy and safety of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infection.
Lee, HL; Nam, HC; Song, MJ; Yang, H, 2016
)
0.43
" Plasma concentrations of daclatasvir and asunaprevir at day 5 of treatment, end-of-treatment response, sustained virological response (SVR), and the frequencies of adverse events were analyzed."( Real-world efficacy and safety of daclatasvir and asunaprevir therapy for hepatitis C virus-infected cirrhosis patients.
Aikata, H; Chayama, K; Hayes, CN; Hiramatsu, A; Honda, Y; Imamura, M; Kawakami, Y; Kawaoka, T; Kobayashi, T; Makokha, GN; Miki, D; Mori, N; Morio, K; Morio, R; Nagaoki, Y; Ochi, H; Takaki, S; Tsuge, M; Tsuji, K; Yokoyama, S, 2017
)
0.46
" The frequencies of treatment-related adverse events in cirrhosis patients were similar to those in chronic hepatitis patients."( Real-world efficacy and safety of daclatasvir and asunaprevir therapy for hepatitis C virus-infected cirrhosis patients.
Aikata, H; Chayama, K; Hayes, CN; Hiramatsu, A; Honda, Y; Imamura, M; Kawakami, Y; Kawaoka, T; Kobayashi, T; Makokha, GN; Miki, D; Mori, N; Morio, K; Morio, R; Nagaoki, Y; Ochi, H; Takaki, S; Tsuge, M; Tsuji, K; Yokoyama, S, 2017
)
0.46
" This combination therapy might offer a safe and effective treatment for chronic HCV infected-patients with compensated cirrhosis."( Real-world efficacy and safety of daclatasvir and asunaprevir therapy for hepatitis C virus-infected cirrhosis patients.
Aikata, H; Chayama, K; Hayes, CN; Hiramatsu, A; Honda, Y; Imamura, M; Kawakami, Y; Kawaoka, T; Kobayashi, T; Makokha, GN; Miki, D; Mori, N; Morio, K; Morio, R; Nagaoki, Y; Ochi, H; Takaki, S; Tsuge, M; Tsuji, K; Yokoyama, S, 2017
)
0.46
" Virological response and adverse events according to age were analyzed."( Safety and efficacy of dual therapy with daclatasvir and asunaprevir for older patients with chronic hepatitis C.
Aikata, H; Chayama, K; Hiramatsu, A; Imamura, M; Kawakami, Y; Kawaoka, T; Kimura, Y; Kobayashi, T; Miki, D; Mori, N; Morio, K; Morio, R; Nagaoki, Y; Nelson Hayes, C; Ochi, H; Takahashi, S; Takaki, S; Tsuge, M; Tsuji, K; Yokoyama, S, 2017
)
0.46
" The frequency of adverse events was similar between younger and older patients."( Safety and efficacy of dual therapy with daclatasvir and asunaprevir for older patients with chronic hepatitis C.
Aikata, H; Chayama, K; Hiramatsu, A; Imamura, M; Kawakami, Y; Kawaoka, T; Kimura, Y; Kobayashi, T; Miki, D; Mori, N; Morio, K; Morio, R; Nagaoki, Y; Nelson Hayes, C; Ochi, H; Takahashi, S; Takaki, S; Tsuge, M; Tsuji, K; Yokoyama, S, 2017
)
0.46
" The most common adverse events were fatigue (one [17%] of six patients receiving sofosbuvir, ledipasvir, and asunaprevir; one [17%] of six patients receiving sofosbuvir, daclatasvir, and simeprevir; and two [33%] of six patients receiving sofosbuvir, daclatasvir, and asunaprevir) and headache (one [17%] patient in each group)."( Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study.
Bassit, L; Benhamou, Y; Chen, G; Chen, J; Hou, J; Hsiao, HM; Ji, D; Jiang, Y; Ke, R; Lau, G; Li, B; Li, F; Li, J; Liu, J; Perelson, AS; Schinazi, RF; Shao, Q; Sun, J; Tao, S; Tsang, ST; Wang, C; Wang, Y; Wong, A; Wong, CL; Wu, V, 2016
)
0.43
" By shortening the duration of therapy from the currently recommended 12 weeks to 3 weeks, we could drastically reduce the cost of therapy and the rate of adverse events."( Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study.
Bassit, L; Benhamou, Y; Chen, G; Chen, J; Hou, J; Hsiao, HM; Ji, D; Jiang, Y; Ke, R; Lau, G; Li, B; Li, F; Li, J; Liu, J; Perelson, AS; Schinazi, RF; Shao, Q; Sun, J; Tao, S; Tsang, ST; Wang, C; Wang, Y; Wong, A; Wong, CL; Wu, V, 2016
)
0.43
" The sustained virological response (SVR) rate after treatment and the adverse events during therapy were compared between CTR-met (patients who met the inclusion criteria) and CTR-unmet (patients who did not meet the inclusion criteria) groups."( The efficacy and safety of dual oral therapy with daclatasvir and asunaprevir for genotype 1b in Japanese real-life settings.
Akuta, N; Arase, Y; Fujiyama, S; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y, 2017
)
0.46
"3%) in CTR-unmet group discontinued therapy because of adverse events other than the ALT elevation."( The efficacy and safety of dual oral therapy with daclatasvir and asunaprevir for genotype 1b in Japanese real-life settings.
Akuta, N; Arase, Y; Fujiyama, S; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y, 2017
)
0.46
"The combination of daclatasvir (DCV) and asunaprevir (ASV) has demonstrated a high sustained virologic response at 12 weeks (SVR12) and a low rate of adverse events in previous clinical studies."( Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study.
Chae, HB; Cho, BW; Kang, YW; Kim, HS; Kim, SB; Kim, SH; Lee, BS; Lee, SH; Lee, TH; Song, IH, 2017
)
0.46
" Adverse events occurred in 10 (13."( Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study.
Chae, HB; Cho, BW; Kang, YW; Kim, HS; Kim, SB; Kim, SH; Lee, BS; Lee, SH; Lee, TH; Song, IH, 2017
)
0.46
" Close monitoring is needed for severe adverse events and treatment failure, which were uncommon."( Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study.
Chae, HB; Cho, BW; Kang, YW; Kim, HS; Kim, SB; Kim, SH; Lee, BS; Lee, SH; Lee, TH; Song, IH, 2017
)
0.46
" The treatment of two patients (2%) was discontinued because of adverse events."( The Real-World Safety and Efficacy of Daclatasvir and Asunaprevir for Elderly Patients.
Ida, Y; Iguchi, M; Kato, J; Kawashima, A; Kitano, M; Maekita, T; Moribata, K; Nakao, T; Shimizu, R; Shingaki, N; Taki, S; Tamai, H, 2018
)
0.48
"Daclatasvir with asunaprevir was a safe treatment, even in patients aged ≥75 years."( The Real-World Safety and Efficacy of Daclatasvir and Asunaprevir for Elderly Patients.
Ida, Y; Iguchi, M; Kato, J; Kawashima, A; Kitano, M; Maekita, T; Moribata, K; Nakao, T; Shimizu, R; Shingaki, N; Taki, S; Tamai, H, 2018
)
0.48
" Safety and effectiveness assessments included incidence of adverse drug reactions (ADRs) and sustained viral response (SVR) rates at 24 weeks (SVR24)."( Safety and effectiveness of daclatasvir and asunaprevir dual therapy in patients with genotype 1 chronic hepatitis C: results from postmarketing surveillance in Japan.
Bando, E; Hatanaka, N; Komoto, A; Nakamura, K; Suzuki, F, 2018
)
0.48
" Three patients discontinued treatment due to adverse events (AEs) including dizziness, dyspnea, and neutropenia."( Efficacy and Safety of Daclatasvir and Asunaprevir in Patients with Hepatitis C Virus Genotype 1b Infection on Hemodialysis.
Jang, JW; Kim, HS; Kim, JH; Kim, SB; Kim, SH; Ko, SY; Kwon, JH; Lee, BS; Lee, SH; Lee, TH; Song, DS; Song, MJ, 2019
)
0.51
" A total of 4 serious adverse events were reported and considered treatment-unrelated."( Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions.
Chen, DS; Chen, PJ; Cheng, PN; Chien, RN; Chuang, WL; Hsu, SJ; Huang, CF; Huang, JF; Huang, YH; Hung, CH; Kao, JH; Lin, CY; Liu, CH; Liu, CJ; Peng, CY; Su, CW; Yu, ML, 2019
)
0.51
"Truncated regimen of DCV + ASV plus ribavirin for 12 weeks was highly effective and safe in HCV-1b patients without NS5A L31/Y93 RAS."( Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions.
Chen, DS; Chen, PJ; Cheng, PN; Chien, RN; Chuang, WL; Hsu, SJ; Huang, CF; Huang, JF; Huang, YH; Hung, CH; Kao, JH; Lin, CY; Liu, CH; Liu, CJ; Peng, CY; Su, CW; Yu, ML, 2019
)
0.51
" Adverse events were reported in 185 (35."( Real-life effectiveness and safety of the daclatasvir/asunaprevir combination therapy for genotype 1b chronic hepatitis C patients: An emphasis on the pretreatment NS5A resistance-associated substitution test.
Chung, WJ; Jang, ES; Jeong, SH; Kim, IH; Kim, KA; Kim, YS; Lee, BS; Lee, YJ, 2019
)
0.51
"Liver malignant tumors (LMTs) represent a serious adverse drug event associated with drug-induced liver injury."( Molecular Initiating Events Associated with Drug-Induced Liver Malignant Tumors: An Integrated Study of the FDA Adverse Event Reporting System and Toxicity Predictions.
Kurosaki, K; Uesawa, Y, 2021
)
0.62

Pharmacokinetics

ExcerptReferenceRelevance
"It is necessary to evaluate the impact of hepatic impairment on the pharmacokinetic profile of direct-acting antiviral agents for the treatment of HCV infection."( The effect of hepatic impairment on the pharmacokinetics of asunaprevir, an HCV NS3 protease inhibitor.
Bedford, W; Bertz, RJ; Chang, I; Child, M; Colston, E; Eley, T; He, B; Kandoussi, H; Marbury, TC; Pasquinelli, C, 2015
)
0.42
" Pharmacokinetic sampling and analyses were performed on days 1 and 7 of dosing."( The effect of hepatic impairment on the pharmacokinetics of asunaprevir, an HCV NS3 protease inhibitor.
Bedford, W; Bertz, RJ; Chang, I; Child, M; Colston, E; Eley, T; He, B; Kandoussi, H; Marbury, TC; Pasquinelli, C, 2015
)
0.42
"Mild hepatic impairment does not meaningfully affect the pharmacokinetic profile of asunaprevir."( The effect of hepatic impairment on the pharmacokinetics of asunaprevir, an HCV NS3 protease inhibitor.
Bedford, W; Bertz, RJ; Chang, I; Child, M; Colston, E; Eley, T; He, B; Kandoussi, H; Marbury, TC; Pasquinelli, C, 2015
)
0.42
" Extensive nonclinical and pharmacokinetic studies have been conducted to characterize the ADME properties of ASV."( Preclinical Pharmacokinetics and In Vitro Metabolism of Asunaprevir (BMS-650032), a Potent Hepatitis C Virus NS3 Protease Inhibitor.
Arora, V; Balakrishnan, A; Browning, M; Knipe, JO; Mcphee, F; Mosure, KW; Phillip, T; Santone, K; Scola, P; Shu, YZ; Sinz, M; Soars, MG, 2015
)
0.65
"Assess the safety, tolerability, and pharmacokinetic (PK) profiles of daclatasvir (DCV) and asunaprevir (ASV) in healthy male Japanese subjects."( Single- and multiple-ascending dose studies to evaluate the safety, tolerability, and pharmacokinetics of daclatasvir and asunaprevir in healthy male Japanese subjects.
Bertz, RJ; Bifano, M; Eley, T; Hiraoka, M; Nagashima, H; Shiozaki, T; Ueno, T; Yamahira, N, 2015
)
0.42
" DCV was readily absorbed, with median tmax of ~ 1 - 2 hours postdose and concentrations declining in a multi-phasic manner."( Single- and multiple-ascending dose studies to evaluate the safety, tolerability, and pharmacokinetics of daclatasvir and asunaprevir in healthy male Japanese subjects.
Bertz, RJ; Bifano, M; Eley, T; Hiraoka, M; Nagashima, H; Shiozaki, T; Ueno, T; Yamahira, N, 2015
)
0.42
" Asunaprevir undergoes rapid absorption, with a time to reach maximum plasma concentration (T max) of 2-4 h and an elimination half-life (t ½) of ≈15-20 h observed in single-ascending dose studies."( Asunaprevir: A Review of Preclinical and Clinical Pharmacokinetics and Drug-Drug Interactions.
Bertz, RJ; Eley, T; Garimella, T; Li, W, 2015
)
0.42
" Raltegravir pharmacokinetic parameters remained unchanged whether administered on or off anti-HCV therapy."( Raltegravir Pharmacokinetics in Patients on Asunaprevir-Daclatasvir.
Barrail-Tran, A; Cheret, A; Furlan, V; Molina, JM; Piroth, L; Rosa, I; Rosenthal, E; Taburet, AM; Vincent, C, 2015
)
0.42
" Areas covered: This article reviews the pharmacodynamic and pharmacokinetic properties of the DCV-TRIO combination."( Pharmacokinetic and pharmacodynamic evaluation of daclatasvir, asunaprevir plus beclabuvir as a fixed-dose co-formulation for the treatment of hepatitis C.
Esposito, I; Marciano, S; Trinks, J, 2018
)
0.48
" The plasma pharmacokinetic profiles of daclatasvir and asunaprevir were described by a 1-compartment model."( Population Pharmacokinetic Analysis for Daclatasvir and Asunaprevir in Japanese Subjects With Chronic Hepatitis C Virus Infection.
Garimella, T; Imai, Y; Ishikawa, H; Osawa, M; Ueno, T, 2018
)
0.48
" The objectives of the analyses were to develop the daclatasvir, asunaprevir, and beclabuvir population pharmacokinetic models for the combination regimen."( Population Pharmacokinetic Analysis of Daclatasvir, Asunaprevir, and Beclabuvir Combination in HCV-Infected Subjects.
Garimella, T; Ishikawa, H; Li, H; Osawa, M; Shiozaki, T; Ueno, T, 2019
)
0.51

Compound-Compound Interactions

ExcerptReferenceRelevance
" Asunaprevir has a low potential to perpetrate drug-drug interactions via CYP3A4, P-glycoprotein and OATP, but is a moderate CYP2D6 inhibitor; concomitant drugs that are substrates of CYP2D6 or P-glycoprotein and have a narrow therapeutic index should be used with care."( Asunaprevir: A Review of Preclinical and Clinical Pharmacokinetics and Drug-Drug Interactions.
Bertz, RJ; Eley, T; Garimella, T; Li, W, 2015
)
0.42
"Quantitative assessment of drug-drug interactions (DDIs) via organic anion transporting polypeptide (OATP) 1B1 is one of the key issues in drug development."( Static Model-Based Assessment of OATP1B1-Mediated Drug Interactions with Preincubation-Dependent Inhibitors Based on Inactivation and Recovery Kinetics.
Futatsugi, A; Kato, Y; Masuo, Y; Taguchi, T, 2020
)
0.56

Bioavailability

ExcerptReferenceRelevance
" These efforts led to the discovery of BMS-929075 (37), which maintained ligand efficiency relative to early leads, demonstrated efficacy in a triple combination regimen in HCV replicon cells, and exhibited consistently high oral bioavailability and pharmacokinetic parameters across preclinical animal species."( Discovery of a Hepatitis C Virus NS5B Replicase Palm Site Allosteric Inhibitor (BMS-929075) Advanced to Phase 1 Clinical Studies.
Anjanappa, P; Bender, JA; Beno, BR; Bora, RO; Colston, E; Gao, M; Gao, Q; Grant-Young, KA; Grasela, DM; Gunaga, P; Hanumegowda, U; Haskell, R; Kadow, JF; Kish, K; Knipe, JO; Lemm, J; Liu, M; Meanwell, NA; Mosure, K; Ng, A; Nickel, A; Parcella, K; Parker, D; Raybon, J; Rigat, K; Roberts, SB; Santone, K; Selvakumar, K; Sheriff, S; Shu, YZ; Sinz, M; Soars, MG; Wan, C; Wang, YK; Witmer, M; Yeung, KS; Zhuo, X, 2017
)
0.46
" Ultimately a compound with oral bioavailability of 100% in rat, and a long half-life in plasma was obtained."( The discovery and optimization of naphthalene-linked P2-P4 Macrocycles as inhibitors of HCV NS3 protease.
Bowsher, M; Friborg, J; Hernandez, D; Hiebert, S; Klei, H; Knipe, JO; Li, R; McPhee, F; Meanwell, NA; Mosure, K; Rajamani, R; Scola, PM; Wang, AX; Wang, YK; Yu, F, 2018
)
0.48
"Objective Since the majority of direct-acting antivirals (DAAs) that are used in the treatment of hepatitis C virus (HCV) infection are mainly metabolized by CYP3A4, it is hypothesized that inter-individual differences in CYP3A4 activity may be associated with the bioavailability of these agents."( Differences in the Serum 4β-hydroxycholesterol Levels of Patients with Chronic Hepatitis C Virus (HCV) Infection: A Possible Impact on the Efficacy and Safety of Interferon (IFN)-free Treatment.
Hirayama, T; Honda, A; Ikegami, T; Kohjima, M; Matsuzaki, Y; Miyazaki, T; Nakamuta, M; Yara, SI, 2018
)
0.48
" The effects of all covariates exceeded the 80% to 125% boundaries, indicating that the asunaprevir soft-gel capsule had higher bioavailability than the tablet and that asunaprevir exposure increased with cirrhosis and increasing baseline and time-varying AST values."( Population Pharmacokinetic Analysis for Daclatasvir and Asunaprevir in Japanese Subjects With Chronic Hepatitis C Virus Infection.
Garimella, T; Imai, Y; Ishikawa, H; Osawa, M; Ueno, T, 2018
)
0.48
" We administered five bRo5 substrates (asunaprevir, cyclosporine, danoprevir, ledipasvir, and simeprevir) intravenously or orally to wild-type and Mdr1a, Bcrp, and Mdr1a/Bcrp knockout rats, calculated the clearance, oral bioavailability, and absorption rate profile of each substrate, and compared the results."( Estimating Efflux Transporter-Mediated Disposition of Molecules beyond the Rule of Five (bRo5) Using Transporter Gene Knockout Rats.
Miyake, T, 2020
)
0.56

Dosage Studied

ExcerptRelevanceReference
" The dosing of asunaprevir in patients with moderate-to-severe hepatic impairment is not recommended."( The effect of hepatic impairment on the pharmacokinetics of asunaprevir, an HCV NS3 protease inhibitor.
Bedford, W; Bertz, RJ; Chang, I; Child, M; Colston, E; Eley, T; He, B; Kandoussi, H; Marbury, TC; Pasquinelli, C, 2015
)
0.42
" Five asunaprevir-treated patients had grade 4 alanine aminotransferase elevations that resolved following discontinuation (n=4) or with continued dosing (n=1)."( Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C.
Bessone, F; Bronowicki, JP; Cohen, D; Eley, T; Gadano, A; He, B; Hernandez, D; Hughes, E; Martorell, CT; McPhee, F; Mendez, P; Pol, S; Ratziu, V; Terg, R; Thuluvath, PJ; Younes, Z; Yu, F, 2014
)
0.4
" Daclatasvir 60 mg once daily and asunaprevir 600 mg twice daily were dosed for 7 days alone followed by combination dosing for 14 days at 30 mg once daily and 200 mg twice daily, respectively."( The pharmacokinetics of daclatasvir and asunaprevir administered in combination in studies in healthy subjects and patients infected with hepatitis C virus.
Bertz, R; Bifano, M; Eley, T; Gardiner, D; Grasela, DM; He, B; Huang, SP; Kandoussi, H; Sevinsky, H; Zhu, K, 2014
)
0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
oligopeptideA peptide containing a relatively small number of amino acids.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Genome polyprotein IC50 (µMol)0.00100.00000.02890.1870AID1350391; AID1392001
Non-structural protein 4A IC50 (µMol)0.00100.00000.02890.1870AID1350391; AID1392001
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Genome polyprotein EC50 (µMol)0.00260.00120.00260.0040AID1368309; AID1368310
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (90)

Assay IDTitleYearJournalArticle
AID1743809Clearance in rat at 5 mg/kg, po or 1 mg/kg, iv2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Discovery of BMS-986144, a Third-Generation, Pan-Genotype NS3/4A Protease Inhibitor for the Treatment of Hepatitis C Virus Infection.
AID1323418Drug uptake in cannulated Sprague-Dawley rat liver at 15 mg/kg administered via oral gavage measured at 24 hrs post dose by LC/MS/MS analysis2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing.
AID1434269Cardiotoxicity in Langendorff perfused rabbit heart assessed as sinoatrial node recovery time at 10 uM perfused for 20 mins (Rvb = 4 +/- 5%)2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Structure-activity relationships of 4-hydroxy-4-biaryl-proline acylsulfonamide tripeptides: A series of potent NS3 protease inhibitors for the treatment of hepatitis C virus.
AID1743807Half-life in dog at 3 mg/kg, po or 1 mg/kg, iv2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Discovery of BMS-986144, a Third-Generation, Pan-Genotype NS3/4A Protease Inhibitor for the Treatment of Hepatitis C Virus Infection.
AID1743785Inhibition of recombinant full length NS3/4A protease in Hepatitis C virus subtype 2a replicon infected in human HuH7 cells preincubated for 3 days followed by substrate addition and measured after 2 hrs by renilla luciferase reporter gene assay2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Discovery of BMS-986144, a Third-Generation, Pan-Genotype NS3/4A Protease Inhibitor for the Treatment of Hepatitis C Virus Infection.
AID1743811Clearance in dog at 3 mg/kg, po or 1 mg/kg, iv2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Discovery of BMS-986144, a Third-Generation, Pan-Genotype NS3/4A Protease Inhibitor for the Treatment of Hepatitis C Virus Infection.
AID1743789Metabolic stability in human liver microsomes assessed as half-life incubated for 5 to 45 mins in presence of NADPH by LC-MS analysis2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Discovery of BMS-986144, a Third-Generation, Pan-Genotype NS3/4A Protease Inhibitor for the Treatment of Hepatitis C Virus Infection.
AID1368312Oral bioavailability in rat at 15 mg/kg2018Bioorganic & medicinal chemistry letters, 01-01, Volume: 28, Issue:1
The discovery and optimization of naphthalene-linked P2-P4 Macrocycles as inhibitors of HCV NS3 protease.
AID1323460Inhibition of recombinant full length HCV genotype 2a HC-J6 NS3/4A protease preincubated for 30 mins followed by substrate addition measured by FRET assay2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing.
AID1743783Inhibition of recombinant full length NS3/4A protease in Hepatitis C virus subtype 1a replicon infected in human HuH7 cells preincubated for 3 days followed by substrate addition and measured after 2 hrs by renilla luciferase reporter gene assay2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Discovery of BMS-986144, a Third-Generation, Pan-Genotype NS3/4A Protease Inhibitor for the Treatment of Hepatitis C Virus Infection.
AID1323421Oral bioavailability in Beagle dog plasma at 3 mg/kg administered via gavage measured up to 24 hrs post dose by LC/MS/MS analysis2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing.
AID1323468Resistance index, ratio of EC50 for HCV genotype 1a H77 harboring NS3-R155K mutant to EC50 for HCV genotype 1a H77 harboring wild type NS32016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing.
AID1368309Inhibition of HCV genotype 1b Con1 NS3 protease infected in human HuH7 replicon cells assessed as reduction in viral replication after 4 days by luciferase reporter gene assay2018Bioorganic & medicinal chemistry letters, 01-01, Volume: 28, Issue:1
The discovery and optimization of naphthalene-linked P2-P4 Macrocycles as inhibitors of HCV NS3 protease.
AID1743814Drug concentration in dog plasma at 3 mg/kg, po measured upto 24 hrs2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Discovery of BMS-986144, a Third-Generation, Pan-Genotype NS3/4A Protease Inhibitor for the Treatment of Hepatitis C Virus Infection.
AID1323476Drug uptake in rabbit heart atrium measured after 60 mins2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing.
AID1323427AUC in cynomolgus monkey plasma at 10 mg/kg administered via oral gavage measured up to 24 hrs post dose by LC/MS/MS analysis2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing.
AID1743817Oral bioavailability in cynomolgus monkey at 3 mg/kg2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Discovery of BMS-986144, a Third-Generation, Pan-Genotype NS3/4A Protease Inhibitor for the Treatment of Hepatitis C Virus Infection.
AID1323467Antiviral activity against HCV genotype 2a JHF-1 in HCV replicon cells assessed as reduction in viral RNA replication by luciferase reporter gene assay2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing.
AID1323461Inhibition of recombinant full length HCV genotype 4a ED43 NS3/4A protease preincubated for 30 mins followed by substrate addition measured by FRET assay2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing.
AID1323409Antiviral activity against HCV genotype 1b Con1 expressing NS3 protease infected in human Huh7.5 cells assessed as reduction in viral RNA replication by luciferase reporter gene assay2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing.
AID1323447Inhibition of recombinant full length HCV genotype 2b HC-J8 NS3 protease in genotype 2a replicon cells by luciferase reporter gene assay2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing.
AID1434271Cardiotoxicity in Langendorff perfused rabbit heart assessed as coronary flow at 10 uM perfused for 20 mins (Rvb = -6 +/- 8%)2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Structure-activity relationships of 4-hydroxy-4-biaryl-proline acylsulfonamide tripeptides: A series of potent NS3 protease inhibitors for the treatment of hepatitis C virus.
AID1323429Cardiotoxicity in rabbit heart assessed as change in sinoatrial node recovery time at 10 uM perfused for 20 mins measured for 1 min by electrophysiology method relative to control2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing.
AID1743805Oral bioavailability in rat at 5 mg/kg2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Discovery of BMS-986144, a Third-Generation, Pan-Genotype NS3/4A Protease Inhibitor for the Treatment of Hepatitis C Virus Infection.
AID1368311Clearance in rat at 5 mg/kg, iv or 15 mg/kg, po2018Bioorganic & medicinal chemistry letters, 01-01, Volume: 28, Issue:1
The discovery and optimization of naphthalene-linked P2-P4 Macrocycles as inhibitors of HCV NS3 protease.
AID1368313Drug concentration in rat liver at 15 mg/kg, po after 24 hrs2018Bioorganic & medicinal chemistry letters, 01-01, Volume: 28, Issue:1
The discovery and optimization of naphthalene-linked P2-P4 Macrocycles as inhibitors of HCV NS3 protease.
AID1368310Inhibition of HCV genotype 1a H77 NS3 protease infected in human HuH7 replicon cells assessed as reduction in viral replication after 4 days by luciferase reporter gene assay2018Bioorganic & medicinal chemistry letters, 01-01, Volume: 28, Issue:1
The discovery and optimization of naphthalene-linked P2-P4 Macrocycles as inhibitors of HCV NS3 protease.
AID1350395Clearance in Sprague-Dawley rat at 15 mg/kg, po administered via gavage or 5 mg/kg, iv administered as 10 mins infusion by LC/MS/MS analysis
AID1323430Cardiotoxicity in rabbit heart assessed as change in sinoatrial node recovery time at 10 uM perfused for 60 mins measured every 10 mins during perfusion by electrophysiology method relative to control2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing.
AID1743802Drug concentration in rat liver at 5 mg/kg, po measured upto 24 hrs2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Discovery of BMS-986144, a Third-Generation, Pan-Genotype NS3/4A Protease Inhibitor for the Treatment of Hepatitis C Virus Infection.
AID1467231Inhibition of HCV NS3/4A protease2017Bioorganic & medicinal chemistry letters, 07-01, Volume: 27, Issue:13
QSAR studies of the bioactivity of hepatitis C virus (HCV) NS3/4A protease inhibitors by multiple linear regression (MLR) and support vector machine (SVM).
AID1323420Clearance in Beagle dog plasma at 1 mg/kg, iv administered as 5 mins infusion measured up to 24 hrs post dose by LC/MS/MS analysis2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing.
AID1323464Inhibition of recombinant full length HCV genotype 4a ED43 NS3 protease in genotype 1b con1 replicon cells by luciferase reporter gene assay2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing.
AID1323410Inhibition of HCV genotype 1a NS3 protease using RET S1 as substrate incubated for 1 min followed by substrate addition measured after 15 mins by FRET assay2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing.
AID1323459Inhibition of recombinant full length HCV genotype 1b J4L6S NS3/4A protease preincubated for 30 mins followed by substrate addition measured by FRET assay2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing.
AID1743786Inhibition of recombinant full length NS3/4A protease in Hepatitis C virus subtype 3a replicon infected in human HuH7 cells preincubated for 3 days followed by substrate addition and measured after 2 hrs by renilla luciferase reporter gene assay2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Discovery of BMS-986144, a Third-Generation, Pan-Genotype NS3/4A Protease Inhibitor for the Treatment of Hepatitis C Virus Infection.
AID1434270Cardiotoxicity in Langendorff perfused rabbit heart assessed as coronary flow at 10 uM perfused for 10 mins (Rvb = -4 +/- 6%)2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Structure-activity relationships of 4-hydroxy-4-biaryl-proline acylsulfonamide tripeptides: A series of potent NS3 protease inhibitors for the treatment of hepatitis C virus.
AID1552078Binding affinity to HCV NS3/4a protease assessed as compound-protein adduct formation per mg protein using radiolabelled compound2019Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16
Discovery of the pan-genotypic hepatitis C virus NS3/4A protease inhibitor voxilaprevir (GS-9857): A component of Vosevi
AID1645924Antiviral activity against HCV2019European journal of medicinal chemistry, Feb-15, Volume: 164A review on HCV inhibitors: Significance of non-structural polyproteins.
AID1350393Half life in human liver microsomes by LC/MS/MS analysis
AID1743800Drug concentration in rat plasma at 5 mg/kg, po measured upto 24 hrs2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Discovery of BMS-986144, a Third-Generation, Pan-Genotype NS3/4A Protease Inhibitor for the Treatment of Hepatitis C Virus Infection.
AID1323463Inhibition of recombinant full length HCV genotype 6a HK-6A NS3/4A protease preincubated for 30 mins followed by substrate addition measured by FRET assay2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing.
AID1447796Antiviral activity against HCV genotype 1b infected in human HuH7 cells at >= 10 times antiviral EC50 after 3 days by luciferase reporter assay2017Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10
Discovery of a Hepatitis C Virus NS5B Replicase Palm Site Allosteric Inhibitor (BMS-929075) Advanced to Phase 1 Clinical Studies.
AID1743812Oral bioavailability in dog at 3 mg/kg2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Discovery of BMS-986144, a Third-Generation, Pan-Genotype NS3/4A Protease Inhibitor for the Treatment of Hepatitis C Virus Infection.
AID1392002Antiviral activity against HCV genotype 1b infected in human Huh7.5 replicon cells assessed as reduction in viral replication incubated for 4 days by luciferase reporter gene assay2018Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10
P3-P4 ureas and reverse carbamates as potent HCV NS3 protease inhibitors: Effective transposition of the P4 hydrogen bond donor.
AID1323470Resistance index, ratio of EC50 for HCV genotype 1b Con1 harboring NS3-D168E mutant to EC50 for HCV genotype 1b Con1 harboring wild type NS32016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing.
AID1323469Resistance index, ratio of EC50 for HCV genotype 1b Con1 harboring NS3-A156V mutant to EC50 for HCV genotype 1b Con1 harboring wild type NS32016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing.
AID1323422AUC in Beagle dog plasma at 3 mg/kg administered via oral gavage measured up to 24 hrs post dose by LC/MS/MS analysis2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing.
AID1350396AUC in Sprague-Dawley rat at 15 mg/kg, po administered via gavage or 5 mg/kg, iv administered as 10 mins infusion by LC/MS/MS analysis
AID1350397Elimination half life in Sprague-Dawley rat at 15 mg/kg, po administered via gavage or 5 mg/kg, iv administered as 10 mins infusion by LC/MS/MS analysis
AID1743810AUC in rat at 5 mg/kg, po or 1 mg/kg, iv2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Discovery of BMS-986144, a Third-Generation, Pan-Genotype NS3/4A Protease Inhibitor for the Treatment of Hepatitis C Virus Infection.
AID1323416Oral bioavailability in cannulated Sprague-Dawley rat plasma at 15 mg/kg administered via gavage measured up to 24 hrs post dose by LC/MS/MS analysis2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing.
AID1743787Inhibition of recombinant full length NS3/4A R155K mutant protease in Hepatitis C virus subtype 1a replicon infected in human HuH7 cells preincubated for 3 days followed by substrate addition and measured after 2 hrs by renilla luciferase reporter gene as2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Discovery of BMS-986144, a Third-Generation, Pan-Genotype NS3/4A Protease Inhibitor for the Treatment of Hepatitis C Virus Infection.
AID1323425Clearance in cynomolgus monkey plasma at 3 mg/kg, iv administered as 5 mins infusion measured up to 24 hrs post dose by LC/MS/MS analysis2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing.
AID1323465Inhibition of recombinant full length HCV genotype 3a S52 NS3 protease in genotype 2a replicon cells by luciferase reporter gene assay2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing.
AID1350398Drug uptake in Sprague-Dawley rat liver at 15 mg/kg, po administered via gavage by LC/MS/MS analysis
AID1350391Inhibition of recombinant full length HCV genotype 1a NS3/4A protease (1027 to 1711 residues) expressed in Escherichia coli strain BL21 (DE3) using RET S1 as substrate incubated for 1 min followed by substrate addition measured after 15 mins by FRET assay
AID1323423Cardiotoxicity in rabbit heart assessed as change in heart rate at 10 uM perfused for 20 mins measured for 1 min by electrophysiology method relative to control2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing.
AID1323411Half life in human liver microsomes2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing.
AID1323417AUC in cannulated Sprague-Dawley rat plasma at 15 mg/kg administered via oral gavage measured up to 24 hrs post dose by LC/MS/MS analysis2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing.
AID1743784Inhibition of recombinant full length NS3/4A protease in Hepatitis C virus subtype 1b replicon infected in human HuH7 cells preincubated for 3 days followed by substrate addition and measured after 2 hrs by renilla luciferase reporter gene assay2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Discovery of BMS-986144, a Third-Generation, Pan-Genotype NS3/4A Protease Inhibitor for the Treatment of Hepatitis C Virus Infection.
AID1323413Inhibition of recombinant full length HCV genotype 2b HC-J8 NS3/4A protease preincubated for 30 mins followed by substrate addition measured by FRET assay2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing.
AID1323419Half life in Beagle dog plasma at 1 mg/kg, iv administered as 5 mins infusion by LC/MS/MS analysis2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing.
AID1323414Half life in cannulated Sprague-Dawley rat plasma at 5 mg/kg, iv administered as 10 mins infusion by LC/MS/MS analysis2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing.
AID1743818AUC in cynomolgus monkey at 3 mg/kg, po or 1 mg/kg, iv2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Discovery of BMS-986144, a Third-Generation, Pan-Genotype NS3/4A Protease Inhibitor for the Treatment of Hepatitis C Virus Infection.
AID1323412Inhibition of recombinant full length HCV genotype 3a S52 NS3/4A protease preincubated for 30 mins followed by substrate addition measured by FRET assay2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing.
AID1743813AUC in dog at 3 mg/kg, po or 1 mg/kg, iv2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Discovery of BMS-986144, a Third-Generation, Pan-Genotype NS3/4A Protease Inhibitor for the Treatment of Hepatitis C Virus Infection.
AID1434267Cardiotoxicity in Langendorff perfused rabbit heart assessed as heart rate at 10 uM perfused for 20 mins (Rvb = -3 +/- 3%)2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Structure-activity relationships of 4-hydroxy-4-biaryl-proline acylsulfonamide tripeptides: A series of potent NS3 protease inhibitors for the treatment of hepatitis C virus.
AID1434268Cardiotoxicity in Langendorff perfused rabbit heart assessed as sinoatrial node recovery time at 10 uM perfused for 10 mins (Rvb = 3 +/- 1%)2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Structure-activity relationships of 4-hydroxy-4-biaryl-proline acylsulfonamide tripeptides: A series of potent NS3 protease inhibitors for the treatment of hepatitis C virus.
AID1323462Inhibition of recombinant full length HCV genotype 5a SA13 NS3/4A protease preincubated for 30 mins followed by substrate addition measured by FRET assay2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing.
AID1743816Clearance in cynomolgus monkey at 3 mg/kg, po or 1 mg/kg, iv2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Discovery of BMS-986144, a Third-Generation, Pan-Genotype NS3/4A Protease Inhibitor for the Treatment of Hepatitis C Virus Infection.
AID1743788Inhibition of recombinant full length NS3/4A D168V mutant protease in Hepatitis C virus subtype 1b replicon infected in human HuH7 cells preincubated for 3 days followed by substrate addition and measured after 2 hrs by renilla luciferase reporter gene as2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Discovery of BMS-986144, a Third-Generation, Pan-Genotype NS3/4A Protease Inhibitor for the Treatment of Hepatitis C Virus Infection.
AID1323426Oral bioavailability in cynomolgus monkey plasma at 10 mg/kg administered via gavage measured up to 24 hrs post dose by LC/MS/MS analysis2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing.
AID1743782Inhibition of recombinant full length NS3/4A protease in Hepatitis C virus subtype 3a infected in human HuH7 cells using Ac-Asp-Glu-Asp (EDANS)-Glu-Glu-Abu-(COO) Ala-Ser-Lys (DABCYL)-NH2 as substrate by FRET assay2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Discovery of BMS-986144, a Third-Generation, Pan-Genotype NS3/4A Protease Inhibitor for the Treatment of Hepatitis C Virus Infection.
AID1447811Antiviral activity against HCV genotype 1b infected in human HuH7 cells co-treated with daclatasvir after 3 days by luciferase reporter assay2017Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10
Discovery of a Hepatitis C Virus NS5B Replicase Palm Site Allosteric Inhibitor (BMS-929075) Advanced to Phase 1 Clinical Studies.
AID1323415Clearance in cannulated Sprague-Dawley rat plasma at 5 mg/kg, iv administered as 10 mins infusion measured up to 24 hrs post dose by LC/MS/MS analysis2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing.
AID1323424Half life in cynomolgus monkey plasma at 3 mg/kg, iv administered as 5 mins infusion by LC/MS/MS analysis2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing.
AID1392001Inhibition of N-terminal poly-His tagged recombinant HCV genotype 1a NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay2018Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10
P3-P4 ureas and reverse carbamates as potent HCV NS3 protease inhibitors: Effective transposition of the P4 hydrogen bond donor.
AID1323428Cardiotoxicity in rabbit heart assessed as change in heart rate at 10 uM perfused for 60 mins measured every 10 mins during perfusion by electrophysiology method relative to control2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing.
AID1323458Inhibition of recombinant full length HCV genotype 1a H77 NS3/4A protease preincubated for 30 mins followed by substrate addition measured by FRET assay2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing.
AID1323471Resistance index, ratio of EC50 for HCV genotype 1b Con1 harboring NS3-D168V mutant to EC50 for HCV genotype 1b Con1 harboring wild type NS32016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing.
AID1350392Antiviral activity against HCV genotype 1b Con1 infected in human HuH7.5 cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene assay
AID1434266Cardiotoxicity in Langendorff perfused rabbit heart assessed as heart rate at 10 uM perfused for 10 mins (Rvb = -1 +/- 1%)2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Structure-activity relationships of 4-hydroxy-4-biaryl-proline acylsulfonamide tripeptides: A series of potent NS3 protease inhibitors for the treatment of hepatitis C virus.
AID1350394Oral bioavailability in Sprague-Dawley rat at 15 mg/kg, administered via gavage by LC/MS/MS analysis
AID1323466Antiviral activity against HCV genotype 1a H77 in HCV replicon cells assessed as reduction in viral RNA replication by luciferase reporter gene assay2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing.
AID1743815Half-life in cynomolgus monkey at 3 mg/kg, po or 1 mg/kg, iv2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Discovery of BMS-986144, a Third-Generation, Pan-Genotype NS3/4A Protease Inhibitor for the Treatment of Hepatitis C Virus Infection.
AID1743808Half-life in rat at 5 mg/kg, po or 1 mg/kg, iv2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Discovery of BMS-986144, a Third-Generation, Pan-Genotype NS3/4A Protease Inhibitor for the Treatment of Hepatitis C Virus Infection.
AID1323433Plasma concentration in rabbit at 30 mg/kg, iv administered as 10 mins infusion measured after 60 mins2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (236)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's213 (90.25)24.3611
2020's23 (9.75)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 14.03

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index14.03 (24.57)
Research Supply Index5.67 (2.92)
Research Growth Index4.52 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (14.03)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials47 (19.34%)5.53%
Reviews27 (11.11%)6.00%
Case Studies20 (8.23%)4.05%
Observational5 (2.06%)0.25%
Other144 (59.26%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]